ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1556394
This article is part of the Research TopicNovel Molecular Targets in Cancer TherapyView all 43 articles
Cost-Effectiveness Analysis of Belzutifan for Advanced Renal Cell Carcinoma
Provisionally accepted
- Fudan University, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objectives: Evaluate the cost-effectiveness of belzutifan, a new treatment option for advanced renal cell carcinoma (aRCC), compared to everolimus from a US healthcare payer perspective.Methods: A 10-year partitioned survival model was developed to assess the costs and effectiveness of belzutifan combined with everolimus, using data from the LITESPARK-005 trials. Survival estimates were made using standard parametric and Royston-Parmar models. Costs and health utilities were gathered from existing literature and public databases. Cumulative costs (in USD), life years, qualityadjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were evaluated and compared. The analysis was conducted from the Veterans Affairs perspective, with a willingness-to-pay threshold of $150,000 ($100,000 to $200,000). Deterministic sensitivity analysis (DSA), probabilistic sensitivity analysis (PSA), and scenario analyses were performed. Subgroup analyses were conducted for seven factors, including gender and age, to assess patient prognosis. Price simulations were also carried out based on the model.
Keywords: cost-effectiveness analysis, belzutifan, Everolimus, Advanced renal cell carcinoma, Price simulation
Received: 06 Jan 2025; Accepted: 01 Jul 2025.
Copyright: © 2025 Chen, Luo and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Li Luo, Fudan University, Shanghai, China
Wenting Zhu, Fudan University, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.